Prothena to cut workforce by 63% amid strategic review

Prothena (PRTA) announced a 63% workforce reduction to cut costs, revising its 2025 net cash burn guidance to $170-$178 million with a projected $298 million year-end cash position; the company's stock is down over 70% in the past year. This restructuring follows the discontinuation of birtamimab development and mixed analyst reactions, including downgrades from BofA and Cantor Fitzgerald despite Roche advancing partnered prasinezumab to Phase 3 trials for Parkinson's and upcoming Phase 1 data for PRX012 in Alzheimer's. Prothena anticipates a 2025 net loss of $240 to $248 million, while potentially receiving up to $105 million in 2026 from partnered programs.

Analysis

Prothena Corporation (PRTA) is undergoing a significant operational restructuring, including a 63% workforce reduction, following a precipitous 70% decline in its stock value over the past year, with its current trading price at $5.75 and market capitalization at $307.35 million. This strategic pivot aims to substantially reduce operating costs and support its remaining programs, with revised 2025 financial guidance projecting a net cash burn from operating and investing activities of $170-$178 million and an anticipated year-end cash position of approximately $298 million. The discontinuation of its birtamimab program for AL amyloidosis, after failing to meet key trial endpoints, is a primary driver for an expected $96 million decrease in annualized net cash burn, though the company still anticipates a 2025 net loss of $240-$248 million, which includes $36 million in non-cash share-based compensation and a $45 million non-cash income tax expense. Despite these setbacks, Prothena highlights positive catalysts such as Roche advancing the partnered drug prasinezumab into Phase 3 trials for early-stage Parkinson's disease, and the imminent initial Phase 1 data for its wholly-owned PRX012 in Alzheimer's disease, expected in August. Furthermore, existing partnerships with Novo Nordisk and Bristol Myers Squibb could yield up to $105 million in clinical milestone payments in 2026. Analyst sentiment, reflected by a moderately negative overall signal (-0.5) and a -0.6 for PRTA specifically, is mixed; BofA Securities downgraded PRTA to Underperform with a $4 price target, and Cantor Fitzgerald moved to Neutral, while Piper Sandler maintained an Overweight rating but reduced its target to $81, contributing to a wide analyst price target range of $4 to $81. InvestingPro analysis suggests the company appears undervalued based on its Fair Value metrics, although the restructuring and recent clinical failures introduce significant uncertainty.

Key Decisions for Investors

• Investors should closely monitor Prothena's execution of its cost-reduction strategy and its ability to manage its projected 2025 net cash burn of $170-$178 million against its anticipated $298 million year-end cash position.
• Acknowledge that the upcoming Phase 1 data for PRX012 in Alzheimer's disease (expected August) and the progress of Roche's Phase 3 trial for prasinezumab are critical near-term catalysts that could substantially influence PRTA's valuation and future prospects.
• Evaluate the high-risk, high-potential-reward profile, considering the significant stock depreciation, recent birtamimab trial failure, and wide analyst price target range ($4 to $81), against the potential of remaining pipeline assets and ongoing partnerships.
• Upcoming business development activities and the company's evaluation of strategic options should be watched for potential impacts on financial health and market position beyond the current restructuring.